Geoffrey M. Parker
- Independent Director
- Director since 2016
Committees
- Audit
Experience
- 2023 - Present Executive Vice Present & Chief Financial Officer, Allogene Therapeutics, Inc, a biotechnology company.
- 2017 - 2023 Chief Operating Officer & Chief Financial Officer, Tricida, Inc, a biotechnology company.
- 2010 - 2015 Chief Financial Officer, Anacor Pharmaceuticals, Inc., a biotechnology company.
- 1997 - 2009 Managing Director and Partner, Healthcare Investment Banking, Goldman Sachs, a multinational investment bank and financial service company.
Other Public Company Directorships
- 2021 - March 2024 Better Therapeutics (NASDAQ: BTTX)
- 2009 - 2022 ChemoCentryx (NASDAQ: CCXI)
- 2016 - 2019 Genomic Health (NASDAQ: GHDX)
- 2016 - 2017 Sunesis Pharmaceuticals (NASDAQ: SNSS)
Notable Experience and Key Skill Sets
- Mr. Parker has developed expertise across the healthcare sector through his extensive experience as a senior executive at multiple biotechnology companies, as a board member at multiple healthcare companies and as an investment banker to the healthcare industry.
- He brings a unique understanding of trends in the healthcare industry including experience with emerging technologies and regulatory strategies.
- Mr. Parker also provides valuable perspective on areas of financial management and capital allocation. He has extensive capital markets and M&A experience as an experienced chief financial officer across three companies and over twenty years as an investment banker.